preprint · medRxiv
Background: People with HIV (PWH) experience an increased burden of cardiovascular disease (CVD), partly driven by chronic immune activation despite antiretroviral therapy (ART). Tuberculosis (TB), a frequent co-infection, may leave persistent inflammatory sequelae even after cure, potentially accelerating hypertension and cardiovascular risk. Evidence on long-term cardiometabolic consequences of prior TB in virally suppressed PWH, particularly sex-specific effects, remains limited. Methods: In a pilot cross-sectional study of 318 PWH, we compared demographics, cardiovascular parameters, and a panel of circulating inflammatory biomarkers between those with and without a history of TB. Logistic regression was used to identify factors associated with TB history in the whole cohort and stratified by sex. Results: In the 31 participants (9.7%) with prior TB, univariate analysis identified significant associations with older age, hypertension, longer ART duration, and elevated IL-6 and soluble ST2. Hypertension was strongly associated with TB history in females (OR 4.41, 95% CI: 3.41 (1.57, 7.41) p=0.003) but not males. In multivariate models adjusted for clinical variables, longer ART duration remained an independent correlate in the full cohort. Sex-stratified multivariate analysis revealed that lower IFN-γ was associated with TB history in males (AOR 0.99, p=0.048), while lower IL-5 was associated with TB history in females (AOR 0.99, p=0.042). Conclusion: A history of TB is associated with hypertension in PWH, particularly among females, and is linked to sex-specific differences in residual inflammatory pathways. These findings suggest that prior TB may contribute to cardiovascular risk in a sex-disparate manner, warranting further investigation.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.64898/2026.01.12.26343987
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.